このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

再発または難治性多発性骨髄腫の参加者におけるテクリスタマブ単剤療法とポマリドマイド、ボルテゾミブ、デキサメタゾン(PVd)またはカルフィルゾミブ、デキサメタゾン(Kd)を比較した研究 (MajesTEC-9)

2026年11月2日 更新者:Janssen Research & Development, LLC

抗CD38モノクローナル抗体を含む1~3回の前治療を受けた再発または難治性多発性骨髄腫の参加者を対象に、テクリスタマブ単剤療法とポマリドマイド、ボルテゾミブ、デキサメタゾン(PVd)またはカーフィルゾミブ、デキサメタゾン(Kd)を比較する第3相ランダム化試験およびレナリドマイド

The purpose of this study is to compare the efficacy of teclistamab with PVd/Kd in Part 1 and to further characterize safety and efficacy of an alternative dosing for teclistamab in Part 2 in participants with relapsed or refractory multiple myeloma.

調査の概要

研究の種類

介入

入学 (実際)

614

段階

  • フェーズ 3

アクセスの拡大

承認済み 一般販売用。 拡張アクセス記録をご覧ください。

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Alaska
      • Anchorage、Alaska、アメリカ、99508
        • Alaska Oncology and Hematology LLC
    • Arizona
      • Gilbert、Arizona、アメリカ、85234
        • Banner MD Anderson Cancer Center
    • California
      • Berkeley、California、アメリカ、94704
        • Alta Bates Comprehensive Cancer Center
      • Long Beach、California、アメリカ、90806
        • MemorialCare Long Beach Medical Center
      • Orange、California、アメリカ、92868
        • University of California Irvine
      • Whittier、California、アメリカ、90602
        • PIH Health Hospital
    • Colorado
      • Aurora、Colorado、アメリカ、80218
        • Rocky Mountain Cancer Centers
    • Connecticut
      • Farmington、Connecticut、アメリカ、06030
        • University of Connecticut
    • Florida
      • Miami、Florida、アメリカ、33136
        • University of Miami Sylvester Cancer Center
      • Orlando、Florida、アメリカ、32806
        • Orlando Health Cancer Institute
      • Weston、Florida、アメリカ、33331
        • Cleveland Clinic Florida
    • Iowa
      • Waukee、Iowa、アメリカ、50263
        • Mission Cancer Blood
    • Louisiana
      • Metairie、Louisiana、アメリカ、70006
        • East Jefferson General Hospital Bone Marrow Transport Clinic
    • Maryland
      • Bethesda、Maryland、アメリカ、20889
        • Walter Reed National Military Medical Center
      • Silver Spring、Maryland、アメリカ、20904
        • Maryland Oncology Hematology P A
    • Massachusetts
      • Boston、Massachusetts、アメリカ、02118
        • Boston University Medical Center
    • Missouri
      • Chesterfield、Missouri、アメリカ、63017
        • Saint Lukes Hospital Saint Lukes Cancer Specialists
    • New Jersey
      • Camden、New Jersey、アメリカ、08103
        • Cooper Health System MD Anderson Cancer Center at Cooper
    • New York
      • New York、New York、アメリカ、10032
        • Herbert Irving Comprehensive Cancer Center Columbia University Medical Center
    • North Carolina
      • Durham、North Carolina、アメリカ、27705
        • Durham VAMC
    • Pennsylvania
      • Lancaster、Pennsylvania、アメリカ、17601
        • Penn Medicine Lancaster General Health
    • Tennessee
      • Nashville、Tennessee、アメリカ、37203
        • Tennessee Oncology
    • Texas
      • Fort Sam Houston、Texas、アメリカ、78234
        • Brooke Army Medical Center
      • Houston、Texas、アメリカ、77030
        • Baylor College of Medicine
      • Houston、Texas、アメリカ、77030
        • Michael E DeBakey VA Medical Center
      • Houston、Texas、アメリカ、77054
        • Harris Health Smith Clinic
    • Utah
      • Salt Lake City、Utah、アメリカ、84106
        • Utah Cancer Specialists
    • Virginia
      • Fort Belvoir、Virginia、アメリカ、22060
        • Alexander T. Augusta Military Medical Center
      • Norfolk、Virginia、アメリカ、23502
        • Virginia Oncology Associates
    • Washington
      • Tacoma、Washington、アメリカ、98405
        • NorthWest Medical Specialties, PLLC
      • Aberdeen、イギリス、AB25 2ZN
        • Aberdeen Royal Infirmary
      • Birmingham、イギリス、B15 2GW
        • University Hospitals Birmingham NHS Foundation Trust
      • Colchester、イギリス、CO4 5JL
        • Colchester Hospital University NHS
      • Liverpool、イギリス、L7 8YA
        • The Clatterbridge Cancer Centre
      • London、イギリス、SW17 0QT
        • St Georges Hospital
      • London、イギリス、SW10 9NH
        • Chelsea And Westminster Hospital
      • Middlesbrough、イギリス、Ts4 3Bw
        • James Cook University Hospital
      • Norwich、イギリス、NR4 7UY
        • Norfolk and Norwich University Hospital
      • Staffordshire、イギリス、ST4 6QG
        • Royal Stoke University Hospital
      • Hadera、イスラエル、3810101
        • Hillel Yaffe Medical Center
      • Haifa、イスラエル、31048
        • Bnai Zion Medical Center
      • Haifa、イスラエル、3436212
        • Carmel Medical Center
      • Petah Tikva、イスラエル、49100
        • Rabin Medical Center
      • Ramat Gan、イスラエル、52621
        • Sheba Medical Center
      • Tel Aviv、イスラエル、64239
        • Tel Aviv Sourasky Medical Center
      • Bologna、イタリア、40138
        • A O U Sant Orsola Malpighi
      • Milan、イタリア、20133
        • Fondazione IRCCS Istituto Nazionale dei Tumori
      • Palermo、イタリア、90127
        • Azienda Ospedaliero Universitaria Policlinico Paolo Giaccone
      • Pisa、イタリア、56126
        • Ospedale Santa Chiara AO Universitaria Pisana
      • Reggio Emilia、イタリア、42123
        • Arcispedale Santa Maria Nuova - IRCCS
      • Roma、イタリア、00128
        • Campus Bio Medico di Roma
      • Siena、イタリア、53100
        • A O Universitaria Senese Ospedale Santa Maria alle Scotte
      • Turin、イタリア、10126
        • A.O.U. Citta della Salute e della Scienza di Torino - Presidio Molinette
      • Udine、イタリア、33100
        • ASUI Santa Maria della Misericordia di Udine
      • Varese、イタリア、21100
        • Ospedale di Circolo e Fondazione Macchi
      • Gūrgaon、インド、122002
        • Fortis Memorial Research Institute
      • Jaipur、インド、302017
        • Bhagwan Mahaveer Cancer Hospital & Research Centre
      • Pune、インド、411004
        • Deenanath Mangeshkar Hospital and Research Centre
      • Amersfoort、オランダ、3813 TZ
        • Meander Medisch Centrum
      • Amsterdam、オランダ、1081 HV
        • VUMC Amsterdam
      • Groningen、オランダ、9700 RB
        • Universitair Medisch Centrum Groningen
      • Utrecht、オランダ、3584 CX
        • UMC Utrecht
      • Blacktown、オーストラリア、2148
        • Blacktown Hospital
      • Fitzroy、オーストラリア、3065
        • St Vincents Hospital Melbourne
      • Melbourne、オーストラリア、3128
        • Box Hill Hospital
      • Murdoch、オーストラリア、6150
        • Fiona Stanley Hospital
      • Nedlands、オーストラリア、6009
        • Sir Charles Gairdner Hospital
      • Salzburg、オーストリア、5020
        • LKH - Universitätsklinikum der PMU Salzburg
      • Vienna、オーストリア、A-1090
        • Medical University Vienna MUV
    • Alberta
      • Calgary、Alberta、カナダ、T2N 5G2
        • Arthur J E Child Comprehensive Cancer Centre
    • New Brunswick
      • Saint John、New Brunswick、カナダ、E2L 4L2
        • Saint John Regional Hospital
    • Ontario
      • Brampton、Ontario、カナダ、L6R 3J7
        • Brampton Civic Hospital
      • Oshawa、Ontario、カナダ、L1G2B9
        • Lakeridge Health Oshawa
    • Quebec
      • Montreal、Quebec、カナダ、H1T 2M4
        • CIUSSS de l Est de l Ile de Montreal Installation Hopital Maisonneuve Rosemont
      • Athens Attica、ギリシャ、115 28
        • Alexandra General Hospital of Athens
      • Pátrai、ギリシャ、263 35
        • Agios Andreas General Hospital of Patra
      • Thessaloniki、ギリシャ、570 10
        • G Papanikolaou Hospital of Thessaloniki
      • Falun、スウェーデン、791 82
        • Falu Lasarett Medicinkliniken Falun
      • Helsingborg、スウェーデン、25287
        • Helsingborgs lasarett
      • Uppsala、スウェーデン、751 85
        • Akademiska Sjukhuset
      • Badalona、スペイン、08916
        • Hosp. Univ. Germans Trias I Pujol
      • Jerez de la Frontera、スペイン、11407
        • Hosp. de Jerez de La Frontera
      • L'Hospitalet de Llobregat、スペイン、08908
        • Institut Catala d Oncologia L Hospitalet
      • León、スペイン、24008
        • Hosp. de Leon
      • Madrid、スペイン、28041
        • Hosp. Univ. 12 de Octubre
      • Madrid、スペイン、28034
        • Hosp. Univ. Ramon Y Cajal
      • Madrid、スペイン、28031
        • Hosp. Univ. Infanta Leonor
      • Murcia、スペイン、30008
        • Hosp. Gral. Univ. J.M. Morales Meseguer
      • Oviedo、スペイン、33011
        • Hospital Universitario Central de Asturias
      • Palma de Mallorca、スペイン、07198
        • Hosp. Son Llatzer
      • Pontevedra、スペイン、36071
        • Hosp. Montecelo
      • Pozuelo de Alarcón、スペイン、28223
        • Hosp. Quiron Madrid Pozuelo
      • Valencia、スペイン、46026
        • Hospital Universitari i Politecnic La Fe
      • Brno、チェコ、625 00
        • Fakultni nemocnice Brno
      • Olomouc、チェコ、779 00
        • Fakultni nemocnice Olomouc
      • Ostrava - Poruba、チェコ、708 52
        • Fakultni Nemocnice Ostrava
      • Prague、チェコ、128 08
        • Vseobecna fakultni nemocnice v Praze
      • Aalborg、デンマーク、9000
        • Aalborg University Hospital
      • Aarhus、デンマーク、8200
        • Aarhus University Hospital
      • Copenhagen、デンマーク、DK-2100
        • Rigshospitalet
      • Herning、デンマーク、7400
        • Regionshospitalet Godstrup
      • Odense C、デンマーク、5000
        • Odense Universitetshospital
      • Vejle、デンマーク、7100
        • Vejle Sygehus
      • Ankara、トルコ(Türkiye)、06200
        • Dr Abdurrahman Yurtaslan Oncology Training and Research Hospital
      • Ankara、トルコ(Türkiye)、06680
        • Liv Hospital Ankara
      • Ankara、トルコ(Türkiye)、06620
        • Ankara University Medical Faculty
      • Ankara、トルコ(Türkiye)、06010
        • Ankara Gulhane Training and Research Hospital
      • Antalya、トルコ(Türkiye)、07100
        • Antalya Training And Research Hospital
      • Denizli、トルコ(Türkiye)、20070
        • Pamukkale University Medical Faculty
      • Istanbul、トルコ(Türkiye)、34214
        • Medipol Mega Universite Hastanesi
      • Samsun、トルコ(Türkiye)、55280
        • Ondokuz Mayis University
      • Cottbus、ドイツ、03048
        • Medizinische Universitat Lausitz Carl Thiem
      • Dresden、ドイツ、01307
        • Universitatsklinikum Carl Gustav Carus Dresden
      • Greifswald、ドイツ、17475
        • Universitätsmedizin Greifswald
      • Hamburg、ドイツ、22763
        • Asklepios Klinik Altona
      • Heidelberg、ドイツ、69120
        • Universitaetsklinikum Heidelberg
      • Marburg、ドイツ、35043
        • Universitaetsklinikum Giessen und Marburg GmbH
      • Tübingen、ドイツ、72076
        • Universitatsklinikum Tubingen
      • Ulm、ドイツ、89070
        • Universitatsklinikum Ulm
      • Zwickau、ドイツ、08060
        • Heinrich-Braun-Klinikum gGmbH
      • Amiens、フランス、80000
        • CHU Amiens - Hopital Sud
      • Caen、フランス、14000
        • Hôpital Côte de Nacre
      • Grenoble、フランス、38700
        • CHU Grenoble
      • Le Mans、フランス、72037
        • Centre Hospitalier du Mans
      • Lille、フランス、59020
        • Hopital Saint Vincent de Paul
      • Montpellier、フランス、34295 cede
        • CHU de Montpellier Hopital Saint Eloi
      • Nantes、フランス、44000
        • CHU Nantes
      • Paris、フランス、75743
        • Hopital Necker Enfants Malades
      • Paris、フランス、75012
        • Hopital Saint-Antoine
      • Paris、フランス、75013
        • Hopital de la Pitie Salpetriere
      • Toulouse、フランス、31100
        • Institut Universitaire du Cancer Toulouse Oncopole
      • Vandœuvre-lès-Nancy、フランス、54500
        • CHU de Nancy - Hopital de Brabois
      • Brasília、ブラジル、70390-140
        • Hospitais Integradaos da Gavea S/A - DF Star
      • Caxias do Sul、ブラジル、95070 560
        • Fundacao Universidade de Caxias do Sul
      • Curitiba、ブラジル、81520-060
        • Hospital Erasto Gaertner- Liga Paranaense de Combate ao Cancer
      • Joinville、ブラジル、89201-260
        • Instituto Joinvilense de Hematologia e Oncologia Ltda Centro de Hematologia e Oncologia
      • Natal、ブラジル、59062 000
        • Liga Norte Riograndense Contra O Cancer
      • Niterói、ブラジル、24020-073
        • Complexo Hospitalar de Niteroi
      • Rio de Janeiro、ブラジル、22775-001
        • Instituto de Educacao, Pesquisa e Gestao em Saude Instituto Americas (COI)
      • Salvador、ブラジル、41253-190
        • IDOR - Regional Bahia
      • São José do Rio Preto、ブラジル、15090-000
        • Funfarme Sjrp
      • São Paulo、ブラジル、05652-900
        • Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein
      • São Paulo、ブラジル、01323-001
        • Hospital Alemao Oswaldo Cruz
      • São Paulo、ブラジル、01509 900
        • Fundacao Antonio Prudente A C Camargo Cancer Center
      • São Paulo、ブラジル、01308-901
        • Sociedade Beneficente de Senhoras Hospital Sirio Libanes
      • São Paulo、ブラジル、04537 081
        • Clinica Medica Sao Germano LTDA
      • São Paulo、ブラジル、01401 002
        • IDOR - Regional Sao Paulo
      • São Paulo、ブラジル、01321-001
        • Real e Benemérita Associação Portuguesa de Beneficência
      • Brasschaat、ベルギー、2930
        • Algemeen Ziekenhuis Klina
      • Haine-St-Paul、ベルギー、7100
        • Jolimont
      • Kortrijk、ベルギー、8500
        • Az Groeninge
      • Leuven、ベルギー、3000
        • Universitair Ziekenhuis Gasthuisberg
      • Liège、ベルギー、4000
        • CHR de la Citadelle
      • Almada、ポルトガル、2805-267
        • Uls Almada Seixal - Hosp. Garcia de Orta
      • Braga、ポルトガル、4710-243
        • Uls Braga - Hosp. Braga
      • Lisbon、ポルトガル、1400-038
        • Champalimaud Foundation Champalimaud Centre
      • Porto、ポルトガル、4200072
        • Instituto Portugues de Oncologia
      • Vila Nova de Gaia、ポルトガル、4434-502
        • Uls Gaia Espinho
      • Gdansk、ポーランド、80 214
        • Uniwersyteckie Centrum Kliniczne
      • Katowice、ポーランド、40 519
        • Pratia Onkologia Katowice
      • Kielce、ポーランド、25 734
        • Swietokrzyskie Centrum Onkologii SPZOZ w Kielcach
      • Lublin、ポーランド、20-081
        • Uniwersytecki Szpital Kliniczny Nr 1 w Lublinie
      • George Town、マレーシア、10450
        • Hospital Pulau Pinang
      • Kota Kinabalu、マレーシア、88200
        • Hospital Queen Elizabeth
      • Kuala Lumpur、マレーシア、59100
        • University Malaya Medical Centre
      • Subang Jaya、マレーシア、47500
        • Subang Jaya Medical Centre
      • Beijing、中国、100020
        • Beijing Chaoyang Hospital
      • Beijing、中国、102208
        • BeiJing JiShuiTan Hospital
      • Changchun、中国、130021
        • The First Bethune Hospital of Jilin University
      • Changsha、中国、410013
        • The Third Xiangya Hospital, Central South University
      • Chengdu、中国、610032
        • Sichuan Provincial Peoples Hospital
      • Chongqing、中国、400030
        • Chongqing University Cancer Hospital
      • Fuzhou、中国、350001
        • Fujian Meidical University Union Hospital
      • Guangzhou、中国、511363
        • Sun Yat -Sen University Cancer Center
      • Hangzhou、中国、310003
        • First affiliated Hospital of Zhejiang University
      • Hangzhou、中国、310003
        • First affiliated Hospital of Zhejiang University 1
      • Harbin、中国、150000
        • Harbin medical university cancer hospital
      • Nanchang、中国、330006
        • The First Affiliated Hospital of NanChang University
      • Nanjing、中国、210008
        • Nanjing Drum Tower Hospital
      • Nanning、中国、530021
        • First Affiliated Hospital of Guangxi Medical University
      • Shanghai、中国、200434
        • Shanghai Fourth People s Hospital
      • Shenyang、中国、110055
        • Shengjing Hospital Of China Medical University
      • Shenzhen、中国、518025
        • Shenzhen 2nd People's Hospital
      • Tianjin、中国、300060
        • Tianjin Medical University Cancer Institute and Hospital
      • Tianjin、中国、301617
        • Institute of Hematology and Blood Diseases Hospital
      • Wenzhou、中国、325000
        • The First Affiliated Hospital of Wenzhou Medical University
      • Wuhan、中国、430023
        • Wuhan Union Hospital
      • Wuxi、中国、214023
        • Wuxi People s Hospital
      • Xi'an、中国、710004
        • The Second Affiliated Hospital of Xi'an Jiaotong University
      • Zhengzhou、中国、450008
        • Henan Cancer Hospital
      • Bunkyō City、日本、113 8519
        • Institute of Science Tokyo Hospital
      • Chiba、日本、260-8717
        • Chiba Cancer Center
      • Gifu、日本、503-8502
        • Ogaki Municipal Hospital
      • Gunma、日本、377-0280
        • National Hospital Organization Shibukawa Medical Center
      • Hirakata、日本、573 1191
        • Kansai Medical University Hospital
      • Hitachi、日本、317-0077
        • Hitachi General Hospital
      • Iruma-gun、日本、350-0495
        • Saitama Medical University Hospital
      • Kamogawa、日本、296-8602
        • Kameda Medical Center
      • Kashiwa、日本、277 8577
        • National Cancer Center Hospital East
      • Kurashiki、日本、710-8602
        • Kurashiki Central Hospital
      • Matsuyama、日本、790-8524
        • Matsuyama Red Cross Hospital
      • Nagakute、日本、480-1195
        • Aichi Medical University Hospital
      • Nagasaki、日本、852-8511
        • JRC Nagasaki Genbaku Hospital
      • Niigata、日本、951 8520
        • Niigata University Medical And Dental Hospital
      • Okayama、日本、701-1192
        • National Hospital Organization Okayama Medical Center
      • Osaka、日本、545 8586
        • Osaka Metropolitan University Hospital
      • Sapporo、日本、060-8648
        • Hokkaido University Hospital
      • Tokyo、日本、113-0033
        • Juntendo University Hospital
      • Tokyo、日本、135 8550
        • The Cancer Institute Hospital of JFCR
      • Yamagata、日本、990 2331
        • Yamagata University Hospital
      • Yamanashi、日本、400-8506
        • Yamanashi Prefectural Central Hospital

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Documented diagnosis of multiple myeloma as defined by the criteria below: (a)Multiple myeloma diagnosis according to International Myeloma Working Group (IMWG) diagnostic criteria (b) Measurable disease at screening as defined by any of the following: (1) Serum M-protein level greater than or equal to (>=)0.5 grams per deciliter (g/dL) (central laboratory); or (2) Urine M-protein level >=200 milligrams (mg)/24 hours (central laboratory); or (3) Serum immunoglobulin free light chain >=10 milligrams per deciliter (mg/dL) (central laboratory) and abnormal serum immunoglobulin kappa lambda free light chain ratio
  • Received 1 to 3 prior lines of antimyeloma therapy including a minimum of 2 consecutive cycles of an anti- cluster of differentiation 38 (CD38) monoclonal antibody at the approved dosing regimen in any prior line and 2 consecutive cycles of lenalidomide in any prior line
  • Documented evidence of progressive disease or failure to achieve a response to last line of therapy based on investigator's determination of response by International myeloma working group (IMWG) criteria
  • Have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2
  • A female participant must agree not to be pregnant, breast-feeding, or plan to become pregnant while enrolled in this study or within 6 months after the last dose of study treatment
  • Must be willing and able to adhere to the lifestyle restrictions specified in this protocol

Exclusion Criteria:

  • Received any prior B cell maturation antigen (BCMA)-directed therapy
  • A participant is not eligible to receive PVd as control therapy if any of the following are present: (1) Received prior pomalidomide therapy, (2) Does not meet criteria for bortezomib retreatment (3) Contraindications or life-threatening allergies, hypersensitivity, or intolerance to pomalidomide or bortezomib, (4) Grade 1 peripheral neuropathy with pain or Grade greater than or equal to (>=) 2 peripheral neuropathy as defined by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0, (5) Received a strong cytochrome P (CYP) 3A4 inducer within 5 half-lives prior to randomization; A participant is not eligible to receive Kd as control therapy if any of the following are present:(1) Received prior carfilzomib therapy, (2) Uncontrolled hypertension, defined as an average systolic blood pressure greater than (>)159 millimeters of mercury (mmHg) or diastolic blood pressure >99 mmHg despite optimal treatment (3) Grade 2 peripheral neuropathy with pain or Grade >=3 peripheral neuropathy as defined by NCI-CTCAE Version 5.0, (4) Contraindications or life-threatening allergies, hypersensitivity, or intolerance to carfilzomib (intolerance defined as prior therapy discontinued due to any adverse event [AE] related to carfilzomib)
  • Received a maximum cumulative dose of corticosteroids of >=140 mg of prednisone or equivalent within 14 days prior to randomization
  • Received a live, attenuated vaccine within 4 weeks before randomization
  • Central nervous system (CNS) involvement or clinical signs of meningeal involvement of multiple myeloma
  • Plasma cell leukemia at the time of screening, Waldenstrom's macroglobulinemia, polyneuropathy, organomegaly, endocrinopathy, M-protein (POEMS) syndrome and skin changes, or primary amyloid light chain amyloidosis

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Teclistamab

Participants will receive teclistamab monotherapy in Part 1 and an alternative dosing regimen of teclistamab in Part 2. Participants who are still receiving the treatment and benefiting from it may enter the long-term extension (LTE) and drug access (DA)-LTE Phases to continue their current treatment until end of the study.

Teclistamab will be administered subcutaneously.

他の名前:
  • JNJ-64007957
実験的:Pomalidomide, Bortezomib and Dexamethasone (PVd) or Carfilzomib and Dexamethasone (Kd)

Participants will receive either PVd or Kd based on principal investigator's choice during Part 1 of the study. Participants who are still receiving the treatment and benefiting from it may enter the LTE and DA-LTE Phases to continue their current treatment until end of the study.

Pomalidomide will be administered orally.

Carfilzomib will be administered intravenously.

Bortezomib will be administered subcutaneously.

Dexamethasone will be administered orally in PVd and intravenously or orally in Kd.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Part 1: Progression-free Survival (PFS)
時間枠:Up to 9 years

PFS is defined as the time from the date of randomization to the date of first documented disease progression, as defined in the International myeloma working group (IMWG) 2016 response criteria, or death due to any cause, whichever occurs first.

Up to 9 years
Part 2: Number of Participants Reporting Cytokine Release Syndrome (CRS) Cases by Severity
時間枠:Up to 9 years

Severity for CRS will be graded as follows: Grade 1: Fever (Temperature greater than or equal to [>=] 38°C); Grade 2: Fever (Temperature >=38°C) with either: hypotension and/or hypoxia requiring low-flow nasal cannula or blow-by; Grade 3: Fever (Temperature >=38°C) with either: hypotension and/or hypoxia requiring high-flow nasal cannula, facemask, nonrebreather mask, or Venturi mask; Grade 4: Fever (Temperature >=38°C) with either: hypotension requiring multiple vasopressors (excluding vasopressin), and/or hypoxia requiring positive pressure and Grade 5: Death.

Up to 9 years

二次結果の測定

結果測定
メジャーの説明
時間枠
Part 1 and 2: Overall Response (Partial Response [PR] or Better)
時間枠:Up to 9 years

Overall response (PR or better) is defined as participants who have a PR or better prior to subsequent antimyeloma therapy in accordance with the IMWG 2016 criteria.

Up to 9 years
Part 1 and 2: Very Good Partial Response (VGPR) or Better Response
時間枠:Up to 9 years

VGPR or better (Stringent Complete Response [sCR]+Complete Response [CR]+VGPR) is defined as participants who achieve a VGPR or better response prior to subsequent antimyeloma therapy in accordance with the IMWG 2016 criteria.

Up to 9 years
Part 1 and 2: Complete Response (CR) or Better Response
時間枠:Up to 9 years

CR or better response is defined as participants who achieve a CR or better response prior to subsequent antimyeloma therapy in accordance with the IMWG 2016 criteria.

Up to 9 years
Part 1: Duration of Response (DOR)
時間枠:Up to 9 years

DOR is defined as the time interval between the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive disease according to the IMWG 2016 response criteria or death due to any cause, whichever occurs first.

Up to 9 years
Part 1: Time to Next Treatment (TTNT)
時間枠:Up to 9 years

TTNT is defined as the time from randomization to the start of subsequent antimyeloma treatment.

Up to 9 years
Part 1: Progression-free Survival on Next-line Therapy (PFS2)
時間枠:Up to 9 years

PFS2 is defined as the time interval between the date of randomization and date of event, which is defined as progressive disease as assessed by investigator on the first subsequent line of antimyeloma therapy, or death from any cause, whichever occurs first.

Up to 9 years
Part 1: Overall Survival (OS)
時間枠:Up to 9 years

OS is defined as the time from the date of randomization to the date of the participant's death due to any cause.

Up to 9 years
Part 1 and 2: Number of Participants with Adverse Events (AEs) by Severity
時間枠:Up to 9 years

Number of participants with AEs by Severity will be reported.

Up to 9 years
Part 1 and 2: Number of Participants with Serious Adverse Events (SAEs) by Severity
時間枠:Up to 9 years

Number of participants with SAEs by Severity will be reported.

Up to 9 years
Part 1 and 2: Number of Participants with Abnormal Laboratory Results
時間枠:Up to 9 years

Number of participants with abnormal laboratory results (such as hematology and chemistry) will be reported.

Up to 9 years
Part 1 and 2: Serum Concentrations of Teclistamab
時間枠:Up to 9 years

Serum concentrations of teclistamab will be reported.

Up to 9 years
Part 1 and 2: Number of Participants with Anti-drug Antibodies (ADAs) to Teclistamab
時間枠:Up to 9 years

Number of participants with ADAs to teclistamab will be reported.

Up to 9 years
Part 1: Change from Baseline in Symptoms, Functioning, and Overall Health-related Quality of Life (HRQoL) as Assessed by European Organization for Research and Treatment of Cancer Quality-of-life Questionnaire Core 30 (EORTC-QLQ-C30)
時間枠:Baseline up to 9 years

Change from baseline in symptoms, functioning, and overall HRQoL assessed by EORTC QLQ-C30 score version 3 will be reported. The EORTC- QLQ-C30 Version 3 includes 30 items that make up 5 functional scales (physical, role, emotional, cognitive, and social), 1 global health status scale, 3 symptom scales (pain, fatigue, and nausea/vomiting), and 6 single symptom items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The item and scale scores are transformed to a 0 to 100 scale. A high scale score represents a higher response level. Thus, a high score for a functional scale represents a high/healthy level of functioning and a high score for the global health status represents high HRQoL, but a high score for a symptom scale/item represents a high level of symptomatology/problems.

Baseline up to 9 years
Part 1: Change from Baseline in Symptoms, Functioning, and Overall HRQoL as Assessed by Multiple Myeloma Symptom and Impact Questionnaire (MySIm-Q) Scale Score
時間枠:Baseline up to 9 years

Change from baseline in symptoms, functioning, and overall HRQoL assessed by MySIm-Q will be reported. The MySIm-Q is a disease-specific PRO assessment complementary to the EORTC-QLQ-C30. It includes 17 items resulting in a symptom subscale and an impact subscale. The recall period is the "past 7 days", and responses are reported on a 5-point verbal rating scale.

Baseline up to 9 years
Part 1: Change from Baseline in Symptoms, Functioning, and Overall HRQoL as Assessed by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
時間枠:Baseline up to 9 years

Change from baseline in symptoms, functioning, and overall HRQoL assessed by PRO-CTCAE will be reported. The National Cancer Institute's (NCI's) PRO-CTCAE is an item library of common adverse events experienced by people with cancer that are appropriate for self-reporting of treatment tolerability. Each symptom selected for inclusion can be rated by up to 3 attributes characterizing the presence/frequency, severity, and/or interference of the AEs. It ranges from 0 to 4 with higher scores indicating higher frequency or greater severity/impact.

Baseline up to 9 years
Part 1: Change from Baseline in Symptoms, Functioning, and Overall HRQoL as Assessed by EuroQol Five Dimension Questionnaire 5-Level (EQ-5D-5L)
時間枠:Baseline up to 9 years

Change from baseline in symptoms, functioning, and overall HRQoL assessed by EQ-5D-5L will be reported. The EQ-5D-5L is a generic measure of health status. The EQ-5D-5L is a 5-item questionnaire that assesses 5 domains including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression plus a visual analog scale rating "health today" with anchors ranging from 0 (worst imaginable health state) to 100 (best imaginable health state).

Baseline up to 9 years
Part 1: Time to Worsening in Symptoms, Functioning, and Overall HRQoL
時間枠:Up to 9 years

Time to worsening in symptoms, functioning, and overall HRQoL will be measured as the interval from the date of randomization to the start date of meaningful change.

Up to 9 years
Part 1: PFS in Participants in High-risk Molecular Features
時間枠:Up to 9 years

PFS in participants in high-risk molecular features will be reported. PFS is defined as the time from the date of randomization to the date of first documented disease progression, as defined in the IMWG 2016 response criteria, or death due to any cause, whichever occurs first.

Up to 9 years
Part 1: Depth of Response in Participants in High-risk Molecular Features
時間枠:Up to 9 years

Depth of response in participants in high-risk molecular features will be reported.

Up to 9 years

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • スタディディレクター:Janssen Research & Development, LLC Clinical Trial、Janssen Research & Development, LLC

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2023年3月29日

一次修了 (実際)

2025年10月13日

研究の完了 (推定)

2031年8月31日

試験登録日

最初に提出

2022年10月5日

QC基準を満たした最初の提出物

2022年10月5日

最初の投稿 (実際)

2022年10月7日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月4日

QC基準を満たした最後の更新が送信されました

2026年11月2日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する